Investors

Webcast ImageWebcast
Coherus Biosciences Inc at Deutsche Bank 42nd Annual Health Care Conference (Live)
05/03/17 at 10:40 a.m. ET
Coherus Biosciences Inc at Deutsche Bank 42nd Annual Health Care Conference
Wednesday, May 3, 2017 10:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Q1 2017 Coherus Biosciences Inc Earnings Conference Call  (Live)
05/08/17 at 4:30 p.m. ET
Q1 2017 Coherus Biosciences Inc Earnings Conference Call
Monday, May 8, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
04/25/17Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
REDWOOD CITY, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), announced today that it completed the initial phases of the Biologics Price Competition and Innovation Act (BPCIA) patent exchange procedure with Amgen for Coherus’ Neulasta (pegfilgrastim) biosimilar candidate, CHS-1701.  Of the two patents originally listed by Amgen in the process, the parties have reached agreement on a single patent for potential litigation, U.S. patent 8,273,707 (the ‘707 pat... 
04/24/17Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th
REDWOOD CITY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017.  At 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing first quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus... 
03/27/17Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
REDWOOD CITY, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Erik Wiberg as Executive Vice President of Corporate Development.  Mr. Wiberg joins Coherus with more than 30 years of experience, including more than 18 years in various business development and corporate finance roles at biopharmaceutical companies, and 13 years in healthcare investment banking and equity research.  In this position, Mr. Wiberg will be responsi... 
03/13/17Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
REDWOOD CITY, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate events and reported financial results for the fourth quarter and full year 2016. Corporate Highlights for the Fourth Quarter 2016 Include: Oncology therapeutic franchise: CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) - Announced that the U.S. FDA has accepted the filing of 351(k) Biologics License Application (BLA) for CHS-1701. The first FDA submissi... 
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Price$19.20
Change (%) Stock is Down 0.7 (3.52%)
Volume434,626
Data as of 04/28/17 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet